G1 Therapeutics
700 Park Offices Drive
Suite 200
Research Triangle Park
North Carolina
27709
United States
Website: http://www.g1therapeutics.com/
231 articles about G1 Therapeutics
-
Retrospective Analysis of Pooled Results from Three Studies Shows COSELA™ (Trilaciclib) Reduced Use of Supportive Care Interventions in Extensive Stage Small Cell Lung Cancer Patients Who Receive the Drug Prior to Chemotherapy
10/7/2021
G1 Therapeutics, Inc., a commercial-stage oncology company, announced results from a retrospective analysis of the pooled results of three randomized trilaciclib studies showing that patients with extensive-stage small-cell lung cancer who received the drug prior to each chemotherapy treatment had significantly lower use of supportive care therapies for chemotherapy-induced myelosuppression than patients who received placebo.
-
G1 Therapeutics Announces Permanent J-Code from Centers for Medicare and Medicaid Services
10/1/2021
G1 Therapeutics, Inc., a commercial-stage oncology company, announced that the permanent J-code for COSELA™ that was issued in July 2021 by the Centers for Medicare & Medicaid Services is now effective for provider billing for all sites of care.
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 01, 2021
10/1/2021
G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for an aggregate of 62,100 shares of G1’s common stock to six employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.
-
G1 Therapeutics Announces New Supplemental COSELA™ (Trilaciclib) Sales Force
9/15/2021
G1 Therapeutics, Inc., a commercial-stage oncology company, announced that it will hire and train a 15-person oncology sales force to supplement the Boehringer Ingelheim oncology commercial team.
-
G1 Therapeutics to Participate in Two Upcoming September 2021 Conferences
9/3/2021
G1 Therapeutics, Inc., a commercial-stage oncology company, announced that the Company will participate in two upcoming virtual investor conferences in September.
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 03, 2021
9/3/2021
G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for an aggregate of 43,400 shares of G1’s common stock to eight employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.
-
G1 Therapeutics Provides Second Quarter 2021 Financial Results and Operational Highlights
8/4/2021
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided a corporate and financial update for the second quarter ended June 30, 2021.
-
G1 Therapeutics Granted New Technology Add-On Payment (NTAP) for COSELA™ (Trilaciclib) by Centers for Medicare & Medicaid Services (CMS)
8/4/2021
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for COSELA™ (trilaciclib) when administered to Medicare beneficiaries in the hospital inpatient setting. It will become effective for provider billing on October 1, 2021.
-
G1 Therapeutics Announces Appointment of Andrew Perry as Chief Commercial Officer
8/2/2021
G1 Therapeutics, Inc., a commercial-stage oncology company, announced the appointment of Andrew Perry as its Chief Commercial Officer.
-
G1 Therapeutics to Provide Second Quarter 2021 Financial Results and Business Update on August 4, 2021
7/28/2021
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2021 on Wednesday, August 4, 2021 at 4:30 p.m. ET.
-
G1 Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for COSELA™ (Trilaciclib) in Combination with Chemotherapy for the Treatment of Locally Advanced or Metastatic Triple Negative Breast Cancer
7/19/2021
G1 Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to COSELA™ (trilaciclib) investigation for use in combination with chemotherapy for the treatment of locally advanced or metastatic triple negative breast cancer (TNBC).
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 02, 2021
7/2/2021
G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for an aggregate of 80,400 shares of G1’s common stock to eight employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.
-
Clinical Catch-Up: June 14-18
6/21/2021
It was another busy week of clinical trial announcements. Here’s a look. -
G1 Therapeutics Announces Addition of Alicia Secor to Board of Directors
6/18/2021
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Alicia Secor to its Board of Directors
-
G1 Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference
6/16/2021
G1 Therapeutics, Inc., a commercial-stage oncology company, announced that G1’s Chief Executive Officer Jack Bailey will participate in the 2021 Raymond James Human Health Innovation Conference.
-
G1 Therapeutics Initiates PRESERVE 3, A Randomized Phase 2 Study of COSELA™ (trilaciclib) in Bladder Cancer
6/14/2021
G1 Therapeutics, Inc., a commercial-stage oncology company, announced that the Company has initiated PRESERVE 3, a Phase 2, randomized, open-label study of COSELA™ administered with first-line platinum-based chemotherapy and the immune checkpoint inhibitor avelumab maintenance therapy in patients with untreated, locally advanced or metastatic urothelial carcinoma.
-
Clinical Catch-Up: June 7-11
6/14/2021
A busy week for clinical trial news as the ASCO meeting wrapped up and the European Hematology Association 2021 Virtual Congress began. Read on for more. -
G1 Therapeutics Presents Phase 1 Data at ASCO Describing Favorable Safety Profile and Evidence of Antitumor Activity of Rintodestrant Combined with Palbociclib in Patients with ER+/HER2- Advanced Breast Cancer
6/4/2021
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today presented results from its Phase 1 study of its oral selective estrogen receptor degrader (SERD), rintodestrant
-
G1 Therapeutics Presents Data on COSELA™ (trilaciclib) at ASCO on Potential Immune Activation in Patients with Newly Diagnosed Extensive-Stage Small Cell Lung Cancer
6/4/2021
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today presented results from analyses evaluating the immune effects of trilaciclib in patients with extensive-stage small cell lung cancer (ES-SCLC) following two Phase 2 clinical trials
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 04, 2021
6/4/2021
G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for an aggregate of 44,200 shares of G1’s common stock to five employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.